


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of the formula (I)



wherein:

- 5 R<sub>2</sub> is selected from hydrogen, hydroxyl, O-alkyl, O-alkenyl, O-benzoyl, O-dibenzoyl, O-alkanoyl, O-alkenoyl, O-aryl, O-heterocyclic, O-heteroaryl or



- 10 wherein R<sub>5</sub> and R<sub>7</sub> are independently be selected from hydrogen, alkanoyl, alkenoyl, dibenzoyl, benzoyl or benzoyl alkyl substituted alkanoyl;  
 R<sub>3</sub> is selected from hydroxyl, O-alkanoyl, O-alkenoyl, O-benzoyl, O-dibenzoyl, O-alkyl, O-alkenyl, O-aryl, O-heterocyclic or O-heteroaryl;  
 R<sub>4</sub> is selected from -CH<sub>2</sub>OH, COOH, CH<sub>2</sub>OCOCH<sub>3</sub>, COO alkyl, COO aryl, CH<sub>2</sub>COO alkyl, COO-heterocyclic, COO-heteroaryl, CH<sub>2</sub>-O aryl, CH<sub>2</sub>O  
 15 heterocyclic or CH<sub>2</sub>O heteroaryl;  
 R<sub>6</sub> is selected from hydrogen or



$R_7$  is selected from hydrogen or alkyl; or  
 pharmaceutically acceptable salts thereof with the proviso that  
 when  $R_2$  is OH,  $R_3$  is OH,  $R_4$  is  $\text{CH}_2\text{OH}$ ,  $R_6$  is xylopyranosyl,  $R_1$  cannot be  
 4.

- 5      2.      A compound as claimed in claim 1 wherein  $R_2$  is hydrogen,  
 benzoyl, dibenzoyl, tigloyl or



wherein  $R_5$  and  $R_7$  are selected from hydrogen, tigloyl, benzoyl or  
 benzoyl alkyl substituted alkanoyl.

- 10      3.      A compound as claimed in claim 1 wherein  $R_3$  is selected from O-  
 acetyl, O-benzoyl, O-dibenzoyl, O-isobutyryl or O-tigloyl.
4.      A compound as claimed in claim 1 wherein  $R_4$  is selected from  
 $\text{CH}_2\text{OH}$ , O-acetyl or hydroxy.
- 15      5.      A compound as claimed in claim 1 wherein  $R_2$  is arabino pyranosyl, 3-  
 (3-benzoyl-2-methylbutanoyl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl, O-benzoyl, O-  
 dibenzoyl, O-tigloyl, 3,4 dibenzoyl  $\alpha$ -L-arabinopyranosyl, 3-(3-benzoyl-2-  
 methylbutyryl-4-tigloyl- $\alpha$ -L-arabinopyranosyl,      3-tigloyl-4-(3-benzoyl-2-  
 methylbutyryl)- $\alpha$ -L-arabinopyranosyl, 3-(3-benzoyl-2 methyl butanoyl-4-  
 benzoyl- $\alpha$ -L-arabinopyranosyl or 3-(3-benzoyl-2 methylbutyryl)-4-benzoyl- $\alpha$ -  
 20      L-arabinopyranosyl.
6.      A compound as claimed in claim 1 wherein  $R_6$  is methyl.
7.      3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-  
 glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutanoyl)-4-benzoyl- $\alpha$ -L-  
 arabinopyranosyl]-22-O-acetyl barringtonol C;
- 25      8.      3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-

- glucuronopyranosyl-21-O-benzoyl barringtogenol C;
9. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-28-O-acetyl barringtogenol C;
10. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-22-O-isobutyryl barringtogenol C;
- 5 11. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21,22-O-dibenzoyl barringtogenol C;
12. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21, 22-O-dibenzoyl barringtogenol C;
- 10 13. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;
14. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;
- 15 15. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21,22-O-tigloyl barringtogenol C;
16. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21,22-O-tigloyl barringtogenol C;
17. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-22-O-benzoyl barringtogenol C;
- 20 18. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3,4-dibenzoyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
19. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3,4-dibenzoyl- $\alpha$ -L-arabinopyranosyl]-28-O-acetyl barringtogenol C;
- 25 20. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-tigloyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
21. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-tigloyl-4-(3-benzoyl-2-methylbutyryl)- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
- 30 22. 3-O- $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-

benzoyl-2-methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl  
barringtonol C; or

23. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-  
glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-benzoyl- $\alpha$ -L-  
5 arabinopyranosyl]-28-O-acetyl barringtonol C.

24. A pharmaceutical composition for treatment and/or control of pain  
comprising a therapeutically effective amount of a compound of any one  
of claims 1 to 23 and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition as claimed in claim 24 wherein the  
10 carrier is a pharmaceutically acceptable excipient.

26. A method of treating and/or controlling pain which includes the step  
of administering to a subject in need of such treatment at least one  
compound as claimed in any one of claims 1 to 23.